The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone is established as a drug to treat patients with type 2 diabetes mellitus. In addition to lowering blood glucose levels, one of the favorable effects of pioglitazone is improvement of systemic chronic inflammation particularly...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes technology & therapeutics 2008-06, Vol.10 (3), p.206-212
Hauptverfasser:	Karagiannis, Efstrathios, Pfützner, Andreas, Forst, Thomas, Lübben, Georg, Roth, Werner, Grabellus, Martin, Flannery, Manja, Schöndorf, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Blood Pressure Body Mass Index Care and treatment Chronic Disease Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Diagnosis Drug Monitoring - methods Drug therapy Female Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - therapeutic use Inflammation Inflammation - prevention & control Male Middle Aged PPAR gamma - agonists Risk factors Thiazolidinediones - therapeutic use Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!